BiTE-话题@MedSci - 梅斯（MedSci）

#BiTE#

10篇内容 | 1248人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2206087, encodeId=fe11220608ef6, content=<a href='/topic/show?id=f8ec34917a' target=_blank style='color:#2F92EE;'>#BiTE#</a> <a href='/topic/show?id=540d114e3764' target=_blank style='color:#2F92EE;'>#双特异性免疫细胞接合器#</a>, objectTitle=BiTE的新形式和新应用, objectType=article, longId=826498, objectId=354a82649887, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240521/1716287241846_1608702.png, objectUrl=/article/show_article.do?id=354a82649887, replyNumber=0, likeNumber=70, createdTime=2024-05-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=354a82649887, moduleTitle=BiTE的新形式和新应用, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=354a82649887)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1506203, encodeId=b8c515062037c, content=<a href='/topic/show?id=f8ec34917a' target=_blank style='color:#2F92EE;'>#BiTE#</a>, objectTitle=Nat Biotech | 针对肿瘤抗原异质性问题，提出CAR-T与BiTEs联合的免疫疗法，产生强有力的特异性抗肿瘤效应, objectType=article, longId=176417, objectId=1f141e6417a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f141e6417a6, replyNumber=0, likeNumber=67, createdTime=2019-07-31, rootId=0, userName=gdsun, userId=a9db9724123, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f141e6417a6, moduleTitle=Nat Biotech | 针对肿瘤抗原异质性问题，提出CAR-T与BiTEs联合的免疫疗法，产生强有力的特异性抗肿瘤效应, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1f141e6417a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506202, encodeId=b36b1506202f7, content=<a href='/topic/show?id=f8ec34917a' target=_blank style='color:#2F92EE;'>#BiTE#</a>, objectTitle=2019 ASCO：Amgen的双特异性抗体BiTE疗法展示出阳性数据, objectType=article, longId=167644, objectId=60cf16e64489, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60cf16e64489, replyNumber=0, likeNumber=88, createdTime=2019-06-06, rootId=0, userName=gdsun, userId=a9db9724123, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60cf16e64489, moduleTitle=2019 ASCO：Amgen的双特异性抗体BiTE疗法展示出阳性数据, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=60cf16e64489)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506201, encodeId=e662150620144, content=<a href='/topic/show?id=f8ec34917a' target=_blank style='color:#2F92EE;'>#BiTE#</a>, objectTitle=安进BiTE免疫疗法疗效惊人：完全缓解率近100%, objectType=article, longId=157075, objectId=456e15e075e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=456e15e075e2, replyNumber=0, likeNumber=89, createdTime=2019-01-01, rootId=0, userName=gdsun, userId=a9db9724123, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=456e15e075e2, moduleTitle=安进BiTE免疫疗法疗效惊人：完全缓解率近100%, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=456e15e075e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506200, encodeId=27e1150620077, content=<a href='/topic/show?id=f8ec34917a' target=_blank style='color:#2F92EE;'>#BiTE#</a>, objectTitle=喜讯！FDA加速批准安进BiTE免疫疗法Blincyto治疗儿科Ph-急性淋巴细胞白血病（ALL）, objectType=article, longId=76569, objectId=1570e65698b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1570e65698b, replyNumber=0, likeNumber=61, createdTime=2016-09-04, rootId=0, userName=gdsun, userId=a9db9724123, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1570e65698b, moduleTitle=喜讯！FDA加速批准安进BiTE免疫疗法Blincyto治疗儿科Ph-急性淋巴细胞白血病（ALL）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1570e65698b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506199, encodeId=cc6015061999b, content=<a href='/topic/show?id=f8ec34917a' target=_blank style='color:#2F92EE;'>#BiTE#</a>, objectTitle=FDA授予安进BiTE免疫疗法Blincyto治疗儿科急性淋巴细胞白血病（ALL）的优先审查资格, objectType=article, longId=67544, objectId=c7dd6e544b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7dd6e544b6, replyNumber=0, likeNumber=70, createdTime=2016-05-06, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7dd6e544b6, moduleTitle=FDA授予安进BiTE免疫疗法Blincyto治疗儿科急性淋巴细胞白血病（ALL）的优先审查资格, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c7dd6e544b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506198, encodeId=c28a1506198e1, content=<a href='/topic/show?id=f8ec34917a' target=_blank style='color:#2F92EE;'>#BiTE#</a>, objectTitle=BiTE免疫疗法Blincyto治疗费城染色体阴性白血病III期临床成功, objectType=article, longId=63534, objectId=bde06353427, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bde06353427, replyNumber=0, likeNumber=66, createdTime=2016-02-21, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bde06353427, moduleTitle=BiTE免疫疗法Blincyto治疗费城染色体阴性白血病III期临床成功, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bde06353427)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506197, encodeId=edbb150619e26, content=<a href='/topic/show?id=f8ec34917a' target=_blank style='color:#2F92EE;'>#BiTE#</a>, objectTitle=ASH 2014：安进BiTE免疫疗法Blincyto有效治疗急性淋巴细胞白血病（ALL）, objectType=article, longId=43800, objectId=5ccf43800e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ccf43800e2, replyNumber=0, likeNumber=70, createdTime=2014-12-11, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ccf43800e2, moduleTitle=ASH 2014：安进BiTE免疫疗法Blincyto有效治疗急性淋巴细胞白血病（ALL）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5ccf43800e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506196, encodeId=124515061965b, content=<a href='/topic/show?id=f8ec34917a' target=_blank style='color:#2F92EE;'>#BiTE#</a>, objectTitle=CAS 与Obiter Research签署多年协议向其研发团队提供SciFinder, objectType=article, longId=42960, objectId=924a42960b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=924a42960b6, replyNumber=0, likeNumber=59, createdTime=2014-11-23, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=924a42960b6, moduleTitle=CAS 与Obiter Research签署多年协议向其研发团队提供SciFinder, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=924a42960b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506195, encodeId=e695150619509, content=<a href='/topic/show?id=f8ec34917a' target=_blank style='color:#2F92EE;'>#BiTE#</a>, objectTitle=安进BiTE免疫疗法收获在望——提交全球BiTE疗法blinatumomab上市申请, objectType=article, longId=40707, objectId=85ed40e07b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85ed40e07b0, replyNumber=0, likeNumber=72, createdTime=2014-09-28, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85ed40e07b0, moduleTitle=安进BiTE免疫疗法收获在望——提交全球BiTE疗法blinatumomab上市申请, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=85ed40e07b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1506194, encodeId=d117150619478, content=<a href='/topic/show?id=f8ec34917a' target=_blank style='color:#2F92EE;'>#BiTE#</a>, objectTitle=百时美施贵宝25亿美元收购丙肝药商Inhibitex, objectType=article, longId=3703, objectId=39fd3e036a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39fd3e036a, replyNumber=0, likeNumber=73, createdTime=2012-01-21, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39fd3e036a, moduleTitle=百时美施贵宝25亿美元收购丙肝药商Inhibitex, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=39fd3e036a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

BiTE

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#BiTE# #双特异性免疫细胞接合器#

BiTE的新形式和新应用

2024-05-22发表于上海

gdsun (审核中...)

前往app查看评论内容

#BiTE#

Nat Biotech | 针对肿瘤抗原异质性问题，提出CAR-T与BiTEs联合的免疫疗法，产生强有力的特异性抗肿瘤效应

2019-07-31

gdsun (审核中...)

前往app查看评论内容

#BiTE#

2019 ASCO：Amgen的双特异性抗体BiTE疗法展示出阳性数据

2019-06-06

gdsun (审核中...)

前往app查看评论内容

#BiTE#

安进BiTE免疫疗法疗效惊人：完全缓解率近100%

2019-01-01

gdsun (审核中...)

前往app查看评论内容

#BiTE#

喜讯！FDA加速批准安进BiTE免疫疗法Blincyto治疗儿科Ph-急性淋巴细胞白血病（ALL）

2016-09-04

docwu2019 (审核中...)

前往app查看评论内容

#BiTE#

FDA授予安进BiTE免疫疗法Blincyto治疗儿科急性淋巴细胞白血病（ALL）的优先审查资格

2016-05-06

docwu2019 (审核中...)

前往app查看评论内容

#BiTE#

BiTE免疫疗法Blincyto治疗费城染色体阴性白血病III期临床成功

2016-02-21

docwu2019 (审核中...)

前往app查看评论内容

#BiTE#

ASH 2014：安进BiTE免疫疗法Blincyto有效治疗急性淋巴细胞白血病（ALL）

2014-12-11

docwu2019 (审核中...)

前往app查看评论内容

#BiTE#

CAS 与Obiter Research签署多年协议向其研发团队提供SciFinder

2014-11-23

docwu2019 (审核中...)

前往app查看评论内容

#BiTE#

安进BiTE免疫疗法收获在望——提交全球BiTE疗法blinatumomab上市申请

2014-09-28

docwu2019 (审核中...)

前往app查看评论内容

#BiTE#

百时美施贵宝25亿美元收购丙肝药商Inhibitex

2012-01-21

科室
- - 订阅+
  - 更多科室
工具
服务